Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

20192,275 citationsJournal Articlebronze Open Access

Authors

Kevin R. Flaherty · University of Michigan

Athol U. Wells · Royal Brompton & Harefield NHS Foundation Trust

Vincent Cottin · Université Claude Bernard Lyon 1

Anand Devaraj · Royal Brompton & Harefield NHS Foundation Trust

Simon Walsh · Royal Brompton & Harefield NHS Foundation Trust

Yoshikazu Inoue · Royal Brompton & Harefield NHS Foundation Trust

Luca Richeldi

Abstract

In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received placebo. Diarrhea was a common adverse event. (Funded by Boehringer Ingelheim; INBUILD ClinicalTrials.gov number, NCT02999178.).

Topics & Keywords

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Eosinophilic Disorders and Syndromes Sarcoidosis and Beryllium Toxicity Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 18, pp. 1718-1727

DOI: 10.1056/nejmoa1908681

Field-Weighted Citation Impact: 180.52